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Background: 5-fluorouracil (5-FU) and cisplatin (CDDP) are used to enhance radiotherapy (RT) effect for head and
neck (HN) cancers. However, the effect of local RT on systemic chemotherapeutics remains unclear. Here, we
evaluated the influence of HN irradiation on the pharmacokinetics (PK) of 5-FU and CDDP in rats as experimental
model.
Methods: The radiation dose distributions of HN cancer patients were determined for the low dose areas, which
are generously deposited around the target volume. Two Gy and 0.5 Gy RT were selected. Single-fraction radiation
was delivered to the HN of Sprague–Dawley rats. 5-FU at 100 mg/kg or CDDP at 5 mg/kg was intravenously
infused 24 hours after radiation.
Results: Radiation at 2 Gy reduced the area under the plasma concentration vs. time curve (AUC) of 5-FU and
CDDP by 16% and 29% compared to non-irradiated controls, respectively. This was accompanied by incremental
total plasma clearance values. Intriguingly, low dose radiation at 0.5 Gy resulted in a similar pharmacokinetic profile,
with a 17% and 33% reduction in the AUC of 5-FU and CDDP, respectively. The changes in AUC of bile, which
increases with RT, were opposite to AUC of plasma for both drugs.
Conclusions: The local HN RT could modulate systemic PK of 5-FU and CDDP in rats. This unexpected RT-PK
phenomena may provide a reference for adjustment of drug administration and is worthy of further investigation.
Trial registration: ClinicalTrials.gov ID NCT01755585 and NCT01609114
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The concurrent use of chemotherapy during radiation
therapy (CCRT) is now the important treatment stratagem
as definitive treatment [1] or adjuvant setting for locally
advanced head and neck cancer [2,3]. For these cases,
5-Fluorouracil (5-FU) and cisplatin (CDDP) are the
most commonly used agents in CCRT to improve the
treatment outcome [4-6]. As radiation techniques improv-
ing, that three-dimensional conformal radiotherapy
(3DCRT), intensity-modulated radiotherapy (IMRT), and
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reproduction in any medium, provided the or(HT) are applied for cancer treatment worldwide. These
are supposed to produce greater target dose conformity
and better critical organ sparing effects with lower
toxicity to normal tissues [7-11]. However, these dose-
painting techniques usually produce a generous low-
dose distribution to the torso which biological effect
remains unclear [12,13].
Radiation therapy (RT) is classically considered as a
local treatment. However, irradiation not only can cause
direct DNA damage effects but also can send signals to
neighboring cells named as the bystander effects [14,15]
or caused longer-range effects called abscopal effects
[16]. Recently, we report that abdominal irradiation no
matter 0.5 Gy considering as off-target area in clinical
practice or 2 Gy, the daily treatment dose, could signifi-
cantly modulate the systemic pharmacokinetics (PK) oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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our next study confirm that local pelvic irradiation with
the liver and kidneys excluded also modulated the sys-
temic PK of 5-FU through stimulating the release of
matrix metalloproteinase-8 (MMP-8) [18]. The field of
RT in the study is excluded the live and the kidneys [18].
However, there are still a few parts of intestines being in-
volved in the whole pelvic field. Leukocyte infiltration of
rat small intestine could be induced by 5-FU [19] and
the passive transport and carrier-mediated transport in
intestinal also influences uptake of 5-FU [20]. Given that
head and neck cancers are common in cancer popula-
tion and CCRT is widely used in clinical practice,
whether the RT-PK phenomena we observed in abdo-
men and pelvis RT with 5-FU exists in head and neck
region is an important issue to be addressed.
CDDP (cis-diammine-dichloro-platinum) is an inorganic
molecule, with a central platinum atom surrounded by two
chlorine atoms and two ammonia molecules [21]. It is
often used as an attractive chemotherapy drug and broadly
used for the treatment of various forms of malignant tu-
mors. There are five major characteristics that are consid-
ered to be responsible for the cytotoxic effects of cisplatin.
As a radiosensitizer, its affinity with the thermalized elec-
tron created by radiation induced ionization within the
DNA molecule and may lead to irreparable damage to the
DNA [22]. Moreover, the inhibition of sublethal damage
repair (SLDR) by cisplatin is demonstrated by experiments
on oxic mammalian cells [23]. Cisplatin also has the ability
to arrest cells in the G2 phase of the cell cycle and, pos-
sibly, to induce their death [24-26]. Research showed that a
cell’s relative radiosensitivity is determined by the cell cycle
phase. Cells are most radiosensitive in the G2/M phase,
less sensitive in the G1 phase and least sensitive during the
latter part of the S phase [27]. In addition, the suppression
of tumour neovascularization by cisplatin has been identi-
fied recently and is under further investigation [28].
In the present study, we investigated the effect of head
and neck RT, including therapeutic fraction size and off-
target dose, on pharmacokinetics of 5-FU and CDDP in
rats. The issues of advance in dose-painting techniques
and adoption of CCRT did not exist in the past era of
conventional 2DRT. Therefore, the conceptual correl-
ation to clinical practice in humans is drawn from point




Prior to pharmacokinetic analysis in rats, we demon-
strated the radiation dose distributions in a head and
neck cancer patient to show the dose-painting concept
that low dose area generously deposited around high-
dose target volume.Targeting and treatment planning
Although only treated by one mode of RT, four sets of radi-
ation planning were performed for each patient including
that for conventional radiotherapy (2DRT), 3DCRT, IMRT,
and HT. The PINNACLE3 version 7.6c planning system
for the former three modes and the Hi Art Planning
system for tomotherapy (Tomotherapy, Inc., Madison,
Wisconsin, USA) were used. The treatment fields for
2DRT, 3DCRT, and IMRT were 2, 5, and 7, respectively.
The field width, pitch, and modulation factor (MF) used
in tomotherapy were 2.5 cm, 0.32, and 3.5, respectively.
A fraction size of 2 Gy was chosen as daily dose. For the
radiation dose to the normal tissues, an isodose line of
0.5 Gy was designed to represent the off-target, general
low-dose area during daily treatment. Notably, there is
no dose-painting result in 2DRT planning, the technique
in the past era. Patient data are collected with the ap-
proval of the Institutional Review Board of Far Eastern
Memorial Hospital (FEMH-IRB-100163-F).
Materials and reagents
The 5-FU/CDDP and high-performance liquid chromatog-
raphy (HPLC)-grade methanol were purchased from Sigma
Chemicals (St. Louis, MO, USA) and Tedia Company, Inc.
(Fairfield, OH, USA), respectively. Milli-Q grade (Millipore,
Bedford, MA, USA) water was used for the preparation of
solutions and mobile phases.
Animals and sample preparation
Adult, male Sprague–Dawley rats (300 ± 20 g body weight)
were provided by the Laboratory Animal Center at
National Yang-Ming University (Taipei, Taiwan). The rats
were anesthetized with urethane 1 g/ml and α-chloralose
0.1 g/ml (1 ml/ kg, i.p.), and were immobilized on a board
to undergo computed tomography for simulation of the
one phase of head and neck RT field. The cranial margin
was set at 5 mm above the head and the caudal margin
was set above the head of humerus. (Figure 1) The con-
ventional technique with anterior-posterior (AP) and PA
portal by 6-MV X-ray was delivered by an linear acceler-
ator (Varian Medical Systems, Palo Alto, CA). The experi-
mental animals were randomized to three separate
experiments for no drug, CDDP and 5-FU administration
and each experiment included at least 6 rats for each with
control (0 Gy), 0.5, and 2 Gy group. All experimental ani-
mal surgery procedures were reviewed and approved by
the animal ethics committee of Far Eastern Memorial
Hospital, Taiwan (FEMH- 100-1-18-A).
Jarugula et al. [29] proved that the dose-normalized
area under the curve (AUC) is significantly higher after
administration of 100 mg/kg than after 50 mg/kg or
10 mg/kg. Thus, we chose 100 mg/kg as a feasible 5-FU
dose in rats for examination of 5-FU pharmacokinetic
parameters, based on previous reports [17,29].
Figure 1 Computed tomography was used for simulation of
the head and neck field. The cranial margin was set at 5 mm
above the head and the caudal margin was set above the head of
humerus. Conventional radiotherapy was used to deliver the
radiation dose via the anterior-posterior (AP) and PA portals.
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subcutaneous, intravenous is 25, 7, 8 and 11 mg/kg, re-
spectively [30]. Therefore, we chose 50% of LD50 of
intravenous CDDP, 5 mg/kg, as a feasible dose in rats
for examination of CDDP pharmacokinetic parameters.
Twenty hours after RT, the rats were administered 5-FU
at 100 mg/kg or 5 mg/kg CDDP in 2 mL of normal saline
by intravenous infusion into the femoral vein over a 2-min
period. A 150-μL blood sample was withdrawn from the
jugular vein with a fraction collector according to a pro-
grammed schedule at 5, 15, 30, 45, 60 min, 1.5, 2, 2.5, and
3 h following drug administration. After centrifugation
and vortexing, the upper organic layer was transferred to anew tube and evaporated to dryness under flowing nitro-
gen. The dried residue was reconstituted with 50 μl of
Milli-Q water (Millipore). A 20-μL aliquot of the solution
was injected to the HPLC-UV system.
Liquid chromatography
5-FU
Chromatographic analysis is performed on a Model LC-
20AT HPLC system (Shimadzu, Tokyo, Japan) equipped
with a Model SPD-20A wavelength UV detector, SIL-20
AC autosampler, and an LC Solution data processing
system. A LiChroCART RP-18e column (Purospher,
250 mm, 5 μm, Merck, Darmstadt, Germany) with a
LiChroCART 4–4 guard column is used for separation.
The mobile phase comprised 10 μM potassium
phosphate-methanol (99: 1, v/v, pH 4.5 adjusted by 85%
phosphoric acid), and the flow rate of the mobile phase
is 1 ml/min. The detection wavelength is set at 266 nm.
Under these conditions, the retention time of 5-FU is
5.4 min. The linearity of calibration curves is dem-
onstrated by the good determination coefficients (r2)
obtained for the regression line. Good linearity is achieved
over the range of 0.01–5 μg/ml, with all coefficients of cor-
relation greater than 0.998. All samples are freshly pre-
pared, including the standard solutions, from the same
stock solution (5 mg/mL). The 0.01-μg/mL limit of quan-
tification is defined the lowest concentration on the cali-
bration curve that could be measured routinely with
acceptable bias and relative SD. The overall mean preci-
sion, defined by the relative SD, ranged from 0.2% to
11.0%. Analytical accuracy is expressed as the percentage
difference of the mean observed values compared to
known concentrations varying from −10.0% to 14.0%. The
recovery results for concentrations of 0.1-10 μg/mL are
92.0%-94.0%.
CDDP
The HPLC system consist of a chromatographic pump
(LC-20AT, Shimadzu, Kyoto, Japan), autosampler (SIL-
20AT, Shimadzu), diode array detector (SPD-M20A,
Shimadzu), and degasser (DG-240). A reversed-phase C18
column (4.6 × 250 mm, particle size 5 μm, Eclipse XDB,
Agilent, Palo Alto, CA, USA) is used for the HPLC separ-
ation. The mobile phase is composed of acetonitrile-10
mM monosodium phosphate (pH 3.0 adjusted by ortho-
phosphoric acid) (70:30, v/v) at a flow-rate of 1.0 ml/min.
The chromatographic run time is 13 min and the detection
wavelength is set at 254 nm. The mobile phase is filtered
through a 0.45 μm Millipore membrane filter and degassed
by sonication 2510R-DTH (Bransonic, CT, USA) before
use. The stock solution of CDDP in 50% acetonitrile
(500 μg/ml) is diluted with 50% acetonitrile to make serial
concentrations of the working standard solutions (1, 5, 10,
50 and 100 μg/ml). Plasma is separated by centrifuging the
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standards are prepared by 5 μl of the working standard so-
lution spik with 45 μl of blank plasma and bile, and then
added 10 μl of freshly prepared 10% diethyldithiocar-
bamate in 0.2 N sodium hydroxide into each sample.
These samples are put into the water bath at 45°C for
30 min to form the derivatization of CDDP. The 100 μl of
internal standard solution (containing 10 μg/ml of magno-
lol dissolved in acetonitrile) is added to the derivative sam-
ples for protein precipitation. The samples are vortexed
and centrifuged at 12,000 rpm for 15 min, after which,
20 μl of supernatants are collected and analysed by the
HPLC system. The calibration curves are represented by
the peak areas ratio of the CDDP to internal standard
spiked in blank samples vs. the concentration of CDDP.
The limits of detection (LOD) and the limit of quantifica-
tion (LOQ) are defined as a signal-to-noise ratio of 3 and
the lowest concentration of the linear regression, respect-
ively. The 0.01-μg/mL limit of quantification is defined the
lowest concentration on the calibration curve that could
be measured routinely with acceptable bias and relative
SD. The overall mean precision, defined by the relative
SD, ranged from 0.6% to 2.2%. Analytical accuracy is
expressed as the percentage difference of the mean ob-
served values compared to known concentrations varying
from −7.4% to 1.0%. The recovery results for concentra-
tions of 0.1-10 μg/mL are 80.7%-82.9.0%.
Pharmacokinetics and data analysis
Pharmacokinetic parameters such as the AUC for concen-
tration vs. time, terminal elimination phase half-life (t1/2),
maximum observed plasma concentration (Cmax), meanFigure 2 An example of isodose distribution using different irradiatio
nasopharyngeal carcinoma patient with transverse, coronal and sagit
B) Three-dimensional conformal radiotherapy (3DCRT). C) Intensive modularesidence time (MRT), total plasma clearance (CL), volume
of distribution at steady state (Vss), and the elimination
constant (Kel) were calculated by the pharmacokinetics
calculation software WinNonlin Standard Edition, Version
1.1 (Scientific Consulting, Apex, NC, USA) using a com-
partmental method.
Statistical methods
The results are presented as means ± standard deviations.
Differences in actuarial outcomes between the groups
were calculated using one-way analysis of variance
(ANOVA), with post hoc multiple comparisons. All ana-
lyses were performed using the Statistical Package for the
Social Sciences, version 12.0 (SPSS, Chicago, IL, USA).
Results
Comparison of treatment plans for different radiation
dosing techniques
A representative example of isodose distribution with
2 Gy to the targets using different techniques is il-
lustrated in Figure 2. It suggests that low dose area gen-
erously deposited around target volume especially in
the era of advanced, conformal radiation techniques.
Plasma and bile pharmacokinetic parameters of 5-FU and
CDDP with head and neck irradiation
5-FU
To verify that local RT modulated the systemic pharmaco-
kinetics of 5-FU, we established an experimental model
using CT-based planning and one phase of head and neck
irradiation in rats merged to our pharmacokinetics assay
system. (Figure 1) Of special interest, radiation at 2 Gyn techniques delivering 2 Gy to the tumor bed for one
tal view. A) The conventional radiation therapy (2DRT).
ted radiotherapy (IMRT). D) Helical tomotherapy (HT).
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radiation at 0.5 Gy representing a dose deposited in the
generous, off-target area in clinical practice. Intriguingly,
we found that irradiation markedly reduced the AUC of
5-FU in rats by 16.9% at 0.5 Gy (p = 0.046) and 15.9% at
2 Gy (p = 0.038), respectively. (Figure 3A) Irradiation sig-
nificantly reduced MRT, and by contrast, increased the CL
of 5-FU when compared to non-irradiated controls
(Table 1). There was no significant difference in the values
of Cmax, Vss and t1/2 within any group.
The AUC of 5-FU in bile of rats after head and neck ir-
radiation markedly increased by 12.2% at 0.5 Gy (p = 0.047)
and 25.0% at 2 Gy (p = 0.001). (Figure 4A) Head and neckFigure 3 The area under the plasma concentration vs. time curve (AU
control, 0.5 and 2 Gy groups with head and neck irradiation.irradiation significantly decreased Cmax and CL, and in
contrast, increased MRT of 5-FU, when compared to non-
irradiated controls. Of interest, 2-Gy irradiation decreased
Cmax (P = 0.004) and CL (P = 0.001), and in contrast, in-
creased MRT (P < 0.001) of 5-FU to an extent greater than
that of the 0.5-Gy group. There was no statistically signifi-
cant difference between the 0.5-Gy and control groups for
T1/2, clearance value, MRT and Vss. (Table 2).
CDDP
Head and neck irradiation also modulated the AUC of
CDDP in rats by decreasing 33% at 0.5 Gy (p = 0.021)
and 29% at 2 Gy (p = 0.028), respectively. (Figure 3B) ByC) of (A) 5-FU 100 mg/kg (B) Cisplatin 5 mg/kg to rats in the
Table 1 Pharmacokinetic parameters of 5-Fluorouracil
(100 mg/kg, i.v.) in rats plasma after head and neck
irradiation with and without 0.5 and 2 Gy
Parameters Controls One phase of head and neck
irradiation
0 Gy 0.5 Gy 2 Gy
AUC (min μg/mL) 4748 ± 360 4017 ± 358* 3993 ± 191*
t1/2 (min) 33.1 ± 11.5 35.5 ± 9.7 39.0 ± 5.6
Cmax (μg/mL) 165 ± 35 165 ± 17 167 ± 39
MRT (min) 37.0 ± 2.8 30 ± 4.5* 29 ± 2.9*
CL (mL/kg/min) 21.2 ± 1.7 25 ± 4.8 27 ± 5.7*
Vss (mL/kg) 785 ± 96 784 ± 88 815 ± 130
AUC area under the plasma concentration, vs. time curve, t1/2 terminal elimination
phase half-life, Cmax maximum observed plasma concentration, MRT mean
residence time, CL total plasma clearance, Vss volume of distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the
control group.
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and 2 Gy (p = 0.019) when compared to non-irradiated
controls (Table 3). There was no significant difference in
the values of MRT, Vss and t1/2 within any group.
Head and neck irradiation markedly increased the AUC
of CDDP in bile of rats by 0.5 Gy (p = 0.015) and at 2 Gy
(p = 0.003), respectively (Figure 4B). When compared to
non-irradiated controls, head and neck irradiation signifi-
cantly increased CL of CDDP at 0.5 Gy (p = 0.001) and
2 Gy (p = <0.001), respectively. There was no statistically
significant difference for Cmax, T1/2, MRT and Vss.
(Table 4).
Discussion
From 2DRT to arc therapy techniques, these therapies
are supposed to produce greater target dose conformity
and better critical organ sparing effects, allowing target
dose escalation, with lower toxicity to normal tissues
[10,31-33]. However, the more beam arranged the more
accompanied low-dose distribution to the torso are
noted. Figures 1 and 2 illustrated the example of isodose
distribution with 2 Gy to the targets in head and neck
patient using the different techniques. We noted that
more than 50% of the normal organ was exposed to
0.5 Gy during daily 2-Gy radiation treatments, except
when using 2DRT to treat patients. These dose-painting
characteristics of modern radiation technique are also
noted in other part of body’s treatment [17]. It suggests
that the low-dose radiation area generously deposits
around the target volume, especially when advanced,
conformal radiation techniques are used.
In the previous studies, we confirm that abdominal or
pelvic irradiation modulates the systemic PK of 5-FU at
0.5 Gy, off-target area in clinical practice, and at 2 Gy,the daily treatment dose for target treatment in an ex-
perimental rat model [17,18]. Additionally, the RT-PK
phenomena are related to the releasing of MMP-8 [18].
The liver and kidneys are excluded in the previous study
to rule out the influences caused by irradiated these
parts because of 80% of 5-FU is catabolized by the liver
[34,35] and 10% to 20% of 5-FU is excreted by the kid-
neys [36]. Furthermore, polymorphonuclear neutrophils
(PMNs) are the main source of MMP-8 in humans and
mice [37,38] and 5-FU often induces leukocyte infiltra-
tion of rat small intestine by the gastrointestinal toxicity
[19]. Additionally, 5-FU is highly absorbable in a gastric
emptying-limited manner with first-pass metabolism
concerning [39] and the uptake of 5-FU in intestinal also
influences by passive transport and carrier-mediated
transport [20]. Therefore, it is difficult to specify the PK
of 5-FU modulated by RT is a general phenomena espe-
cially when RT field still cover partial intestines.
In the current study, only HN was irradiated for PK
analysis. (Figure 1) the AUC of 5-FU in rats was reduced
not only at 0.5 Gy but also at 2 Gy. (Figure 3A) Add-
itionally, the AUC of 5-FU in bile of rats after HN irradi-
ation increased for both irradiation groups. (Figure 4A)
Furthermore, the CL rate in irradiation groups were in-
creased in plasma and decreased in bile study. (Tables 1
and 2) It suggests that local irradiation may modulate
the systemic PK of 5-FU and facilitate the excretion of
5-FU discernible to the area irradiated.
CDDP and 5-FU combination treatments are reported
to be one of the most active chemotherapeutic regimens
for the patients with head and neck squamous cell carcin-
oma [4-6]. Although both CDDP and 5-FU induce apop-
tosis through caspase activation, the apoptosis induced by
CDDP was reported to be involved in caspase-9 [40], in
contrast to the involvement of caspase-1, -3 and −8 in
5-FU-induced apoptosis [41]. Additionally, CDDP is known
to intercalate into DNA at any phase of the cell cycle
[42,43], causing the cytotoxic effect and reducing the cellu-
lar viability [44]. 5-FU inhibits the function of RNA or
DNA synthesis [45,46] and causes the cytostatic effect ac-
companied by the growth arrest at the G1/S boundary of
the cell cycle [47]. In this study, the AUC of CDDP in
plasma was decreased no matter at 0.5 Gy or 2 Gy
(Figure 3B) and increased the CL of CDDP when com-
pared to non-irradiated controls (Table 3). Additionally,
the AUC of CDDP in bile of rats was increased by 0.5 Gy
and 2 Gy. (Figure 4B) (Table 4). It suggests that similar
modulation also between head and neck irradiation and
the systemic PK of CDDP with facilitating the excretion of
CDDP. Irradiation is not only modulating PK of 5-FU but
also modulating PK of CDDP. Because this RT-PK
phenomenon exists in drugs with different mechanisms of
action, it implicates that RT may modulate PK in a way in-
dependent to downstream drug targets.
Figure 4 The area under the bile concentration vs. time curve (AUC) of (A) 5-FU 100 mg/kg (B) Cisplatin 5 mg/kg to rats in the control,
0.5 and 2 Gy groups with head and neck irradiation.
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the role of MMP-8 as observed in abdominal and pelvic
RT is not proved in the current study. The role of abdom-
inal and pelvic RT-induced MMP-8 in modulating 5-FU
pharmacokinetics has been demonstrated. Whether this
soluble factor has an impact on head and neck RT-
modulated pharmacokinetics of 5-FU and CDDP remains
to be determined. Second, this study is the effects of ir-
radiation followed by chemotherapy with one-shot design
rather than fractionation RT as daily practice. For proof of
concept, we designed the use of one shot irradiation
followed by chemotherapy. In clinical use of fractionatedRT and periodically concurrent chemotherapy, the previ-
ous daily fraction of RT may modulate the PK of chemo-
therapeutics administered in the consecutive day. In the
conducting clinical trial, we planned to validate this RT-
modulated PK phenomenon in patients receiving CCRT
with fractionated RT. Third, this study is the effects of ir-
radiation followed by chemotherapy but concurrent
chemotherapy with radiotherapy is the usual way that
applied in the clinical practice. However, patients with rec-
tal cancer who receive preoperative radiotherapy, add
ing fluorouracil-based chemotherapy preoperatively or
postoperatively has no significant effect on survival.
Table 4 Pharmacokinetic parameters of CDDP (5 mg/kg,
i.v.) in rats bile after head and neck irradiation with and
without 0.5 and 2 Gy
Parameters Controls One phase of head and neck
irradiation
0 Gy 0.5 Gy 2 Gy
AUC (min μg/mL) 262 ± 52 542 ± 192* 611 ± 66*
t1/2 (min) 32 ± 15 27 ± 5.1 28 ± 7.8
Cmax (μg/mL) 12 ± 1.0 19 ± 10 18 ± 2.8
MRT (min) 28 ± 9.4 33 ± 8.3 32 ± 11.6
CL (mL/kg/min) 19 ± 3.4 10 ± 2.9* 8.2 ± 0.9*
Vss (mL/kg) 544 ± 202 337 ± 150 257 ± 94
AUC area under the plasma concentration, vs. time curve, t1/2 terminal
elimination phase half-life, Cmax maximum observed plasma concentration
MRT mean residence time, CL total plasma clearance, Vss volume of
distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the
control group.
Table 2 Pharmacokinetic parameters of 5-Fluorouracil
(100 mg/kg, i.v.) in rats bile after head and neck
irradiation with and without 0.5 and 2 Gy
Parameters Controls One phase of head and neck
irradiation
0 Gy 0.5 Gy 2 Gy
AUC (min μg/mL) 1218 ± 22 1366 ± 86* 1522 ± 111*
t1/2 (min) 9.4 ± 0.5 9.2 ± 0.2 13.3 ± 1.1
*
Cmax (μg/mL) 129 ± 22 104 ± 14* 88 ± 17*
MRT (min) 10.0 ± 1.0 10.7 ± 0.5 14.5 ± 0.6*
CL (mL/kg/min) 80.3 ± 2.3 76.3 ± 5.4 65.6 ± 4.5*
Vss (mL/kg) 812 ± 96 820 ± 66 952 ± 69
AUC area under the plasma concentration, vs. time curve, t1/2 terminal
elimination phase half-life, Cmax maximum observed plasma concentration,
MRT mean residence time, CL total plasma clearance, Vss volume of
distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the
control group.
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nificant benefit with respect to local control [48]. Add-
itionally, fluorouracil and cisplatin to radiotherapy
within 16 hours after the first radiation fraction was ad-
ministered that significantly improved the survival rate
of women with locally advanced cervical cancer [49].
These data explain the importance of adding chemo-
therapy to RT but rather than time sequence of drug de-
livering. The findings for modulation of drug PK by
local RT, as demonstrated in previous and this study,
may provide a clue and a research platform to clarify
this controversy. Finally, the data of pharmacokinetics
for head and neck cancer patients during CCRT is not
collected in the current study. Thus, the further studyTable 3 Pharmacokinetic parameters of CDDP (5 mg/kg,
i.v.) in rats plasma after with or without head & neck
irradiation at control, 0.5 and 2 Gy
Parameters Controls One phase of head and neck
irradiation
0 Gy 0.5 Gy 2 Gy
AUC (min μg/mL) 722 ± 164 484 ± 52* 511 ± 138*
t1/2 (min) 269 ± 108 215 ± 88.5 172 ± 44.6
Cmax (μg/mL) 15.0 ± 2.2 9.6 ± 0.7* 10.1 ± 1.3*
MRT (min) 291 ± 131 248 ± 97.5 249 ± 116
CL (mL/kg/min) 4 ± 1.2 6.8 ± 1.1* 6 ± 0.9*
Vss (mL/kg) 1233 ± 470 1621 ± 520 1626 ± 683
AUC area under the plasma concentration, vs. time curve, t1/2 terminal
elimination phase half-life, Cmax maximum observed plasma concentration,
MRT mean residence time, CL total plasma clearance, Vss volume of
distribution at steady state.
*The mean difference is significant at the 0.05 level in comparison to the
control group.for RT-PK phenomena of 5-FU and CDDP in head and
neck cancer patients is warranted in the future.
Conclusions
To our best knowledge, this is the first study to prove
that head and neck irradiation without liver, kidneys and
intestines irradiation that can significantly modulate the
systemic pharmacokinetics of 5-FU and CDDP at dosage
levels for both the target (2 Gy) and off-target areas
(0.5 Gy). This study may provide an experimental clue
to understand the unclear biological effects of generous,
low-dose RT in the era of highly conformal RT in head
and neck treatment. For head and neck irradiation with
concurrent 5-FU and CDDP, this unexpected RT-PK
phenomena may provide a reference for adjustment of
drug administration during CCRT and is worthy of fur-
ther investigation in clinical practice.
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